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BACKGROUND
METHODS
PERSONALITY, ANXIETY, DEPRESSION AND ATOPIC DERMATITIS SEVERITY
A CROSS SECTIONAL STUDY
AIM
Evaluate the association between anxiety
and depression levels, personality traits
and disease severity in adult patients
previously diagnosed with AD.
CAPSULE 
SUMMAR
Y
A total of 31 patients (mean age of 29
yo), recruited from the community and
allergy and dermatology outpatient
settings were included.
Anxiety and depression levels were
evaluated through HADS – Hospital
Anxiety and Depression Scale
Personality traits were evaluated
through NEO Five-Factor-Inventory.
RESULTS
CONCLUSION
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Mean Duration of Disease 19 years
Atopy
Undetermined 10%
Yes 73%
No 17%
Asthma
Yes 72%
No 28%
Table 1: Sample summary descriptive statistics
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duration of disease and
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We evaluated Atopic Dermatitis severity and its relation with 
personality traits, anxiety and depression. Interestingly anxiety 
presented no significant association while depression and several 
personality traits were closely related to SCORAD and DLQI
A linear regression model for Anxiety and
Depression and its relation with SCORAD
presented a p=0,34 for depression while
anxiety presented no statistical association.
In a linear model using personality traits,
Extroversion and Agradability suggested na
association with SCORAD (p=0,054 and
p=0,063 respectively)
Previous studies clearly stated a relation between Psoriasis or other imune-mediated diseases and several psychological
factos; our study corroborates these findings concerning AD.
While anxiety presented no association, depression showed an importante impact on severity of AD in our sample. Further
studies are needed in order to establish a cause-effect relationship.
Both extroversion and agradability suggested a relationship with AD severity. We expect this to become statistical significant
by the time all the patients are fully evaluated.
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ABSTRACT 
 
Background/ Objectives 
Atopic Dermatitis (AD) is a multifactorial, immune mediated, chronic and relapsing skin 
disease, with significant emotional distress, sleep disturbance and Quality of Life (QoL) 
impairment of patients and their families. Personality traits have been assumed to play a pivotal 
role in AD, with a higher rate of psychological problems, mainly anxiety and depression. Our aim 
was to evaluate the association between anxiety and depression levels, personality traits and 
disease severity in adolescents and adult patients with long term AD. 
Methods 
A total of 69 patients, over 16yo and previously diagnosed with AD were recruited; those 
presenting severe comorbidities or other immune mediated skin diseases were excluded. Anxiety 
and depression levels were evaluated through Hospital Anxiety and Depression Scale (HADS) 
and personality traits through NEO Five Factor Inventory. AD severity was evaluated through 
SCORAD severity score (0-103) and QoL (0-30) through Dermatology Life Quality Index 
(DLQI). T student test and linear regression model were used when appropriate. 
Results 
A total of 44 patients were enrolled, mean age (SD) of 31 (13) yo, 39% males. SCORAD 
mean (SD) was 45 (28) and DLQI was 8 (5). 34% of patients presented anxiety, 14% depression. 
SCORAD did not present correlation with anxiety while a positive correlation was suggested with 
depression (R = 0.3; p=0.068), mean comparison with each trait of personality traits showed 
significant differences for Consciousness (p=0.039). SCORAD was the strongest predictor of 
QoL. 
Conclusions 
Depression was marginally associated with more severe AD. Conscientiousness was 
associated with less severe disease. Psychotherapeutic interventions may benefit AD patients  
INTRODUCTION 
 
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease with a considerable 
social burden in both patients and their families 1,2. It has an estimated prevalence of up to 20% 
in children and 2% in adults 3,4 and a complex pathophysiology involving skin barrier defects and 
immunological deregulation in genetically predisposed individuals 5-7. Pruritus is a major 
symptom and an important cause of sleep disruption.  Skin is the largest organ of the body and a 
healthy normal skin is very important for the individual’s physical and mental well-being. Thus, 
skin scaling, oozing and redness can cause a significant impact on external appearance and social 
disability 2.  
Besides external insults, psychological factors can modulate AD symptoms and flares. 
Among all psychiatric disorders anxiety and depression are observed more commonly 8. 
Psychological stress and its relation with allergic diseases have been, for long, a matter of concern 
9,10. Concerning AD, an association has been proposed between disease exacerbations, anxiety 
and stress9,10 but few studies are published in patients with long term disease. Personality traits as 
neuroticism can predict health outcomes including anxiety, depression and tendency to 
somatization 11. AD patients have already been described with lower self-competence and self-
efficacy, when compared with healthy individuals, and some authors even suggested that 
neuroticism is associated to the atopic eczema patient profile 12,13. However no consistent relations 
have been previously found between AD severity and a distinct personality profile 14,15. 
Our study aims at evaluating the relation between anxiety, depression levels, and the 5-main 
domains of personality assessed by questionnaire, with AD severity in a group of adolescents and 
adult patients. 
 
 
  
METHODS 
 
Participants and study design 
Subjects: Adolescent (> 16 years old) and adult patients previously diagnosed with AD were 
invited to participate. Patient recruitment was performed through advertisement, in both television 
and local newspapers, through advertisement in scientific workshops and through peer-to-peer 
referral in local medical community, between November 2011 and June 2012. A total of 69 
patients aged 16 to 85 years with a previous diagnosis of atopic dermatitis according to Anakin 
Rajka diagnostic criteria irrespective of severity or current treatment, were eligible 16. Patients 
with other forms of dermatitis such as contact, seborrheic dermatitis, nummular eczema, 
occupational dermatitis, hand eczema, psoriasis or with any clinically relevant major systemic 
disease that could potentially complicate interpretation of study results, were excluded. 
 
Assessments: AD patients were characterized according to disease duration, medication 
needed to control symptoms and asthma status (previous self-reported diagnosis). AD severity 
was assessed by an evaluating physician (Allergist or Dermatologist) through SCORAD (score 
of severity of Atopic Dermatitis) from 0-103: a composite score of  disease extension, intensity 
as the sum of individual scores for erythema, oedema/papules, oozing/ crusts, excoriation, 
lichenification, and skin dryness, as well as subjective symptoms including pruritus and sleep-
loss, assessed by the patient . 
Disease severity was recoded through the score in SCORAD and classified into mild if 
SCORAD < 25; moderate if 25-50, and severe if > 50.  
Anxiety and Depression were evaluated through the Portuguese version of the Hospital 
Anxiety and Depression Scale (HADS) 17. This test has two separate scales: one for anxiety 
(HADS-A) and one for depression (HADS-D). Both sub-scales are graded from 0 (best) to 21 
(worst) and then divided into Normal (if score ≤ 7), mild (if score from 8 to 10), moderate (11 to 
14) and severe (if ≥ 15). This score has already been validated to the Portuguese population 18. 
Personality traits were assessed through the short version of the NEO Personality Inventory 
(NEO-PI-R) 19. This 60-item multiple choice questionnaire evaluates the 5 main dimensions of 
personality: Neuroticism (as a measure for emotional stability or lability), Openness (as the 
predisposition to new experiences), Extraversion (as the main energy focus being held in- or 
outwards), Agreeableness (as the ability to deal with others) and Conscientiousness (as the sense 
of right and wrong towards own behaviour). NEO-FFI has already been validated to the 
Portuguese population 20. 
Quality of Life (QoL) was assessed by the Dermatology Life Quality Index 21, validated in 
the Portuguese population; a 10-item questionnaire for patients above 16 years, aiming at 
evaluating the patients’ perception of the impact of the skin diseases on several aspects of QoL, 
over the past week. Scores range from 0 (no effect) to 30 (severe impairment on QoL). Patients 
scoring 0 to 1 were categorised as having no impact on QoL, 2 to 5 as having a mild impact, 6 to 
10 as a moderate impact, 11 to 20 as a severe impact and patients scoring 21 to 30 as having an 
extremely severe impact on QoL.  
 
Statistical analysis 
Normality of variables was assessed through the Kolmogorov-Smirnov test. Personality traits 
were recoded into a 3-item category with patients scoring ‘low’ or ‘very low’ grouped into ‘Low’ 
and patients scoring ‘high’ or ‘very high’ grouped into ‘High’. Comparison of categorical 
variables with continuous variables presenting a normal distribution, was performed using 
independent-samples t-test and one-way ANOVA test; when significant differences were found 
in one-way ANOVA test, a post-Hoc Bonferroni correction was performed. Correlation between 
continuous variables was achieved through the Pearson correlation coefficient. For computing a 
multiple linear regression model, DLQI, anxiety and depression scores were used as continuous 
variables. Statistical analysis was performed using SPSS 21.0®. Significant differences were 
considered with p-values under 0.05.  
The study was approved by the local ethics committee. All participants provided their oral 
informed consent and were free to withdraw from the study if desired.  
 
  
RESULTS 
 
From the 69 invited patients, a total of 44 (64%) were included, mostly female (61%), mean 
age (SD) of 31 years (13), 7% were less than 18. The majority (73%) was atopic and slightly more 
than half (61%) had asthma. Most patients had moderate (41%) to severe (34%) AD, with 66% 
of them presenting the disease for more than 10 years. Most patients had a moderate (36%) or 
severe (32%) impact on QoL. (Table 1). 
Anxiety was present in 34% of patients (n=15), mostly mild (n=9). Only 14% of patients (n= 
6) presented depression (five mild, one moderate). As for personality traits, most patients scored 
normal in all five dimensions. (Table 2). When comparing extraversion scores in patients scoring 
high or very high in neuroticism with those scoring low or very low, the first group presented 
lower extraversion scores (with only 43% of patients scoring high in extraversion vs 78% in the 
second group). 
 
SCORAD evaluation 
No significant differences were found between SCORAD concerning patient’s gender 
(p=0.275). Atopic status or asthma, (p=0.313 and p=0.9941 respectively) patients’ age (p=0.163) 
and disease duration (p=0.885). 
 
Anxiety, Depression and Personality traits 
Anxiety score presented no significant correlation with SCORAD (p = 0.331); however, a 
positive correlation between depression and SCORAD scores was suggested (p = 0.068, r = 0.28). 
Significant differences in SCORAD means were only found between groups with different scores 
in conscientiousness, with patients scoring ‘Normal’ presenting with a significantly higher value 
when comparing to patients scoring ‘High’ (post-Hoc Bonferroni correction; p=0.037). No 
significant differences were found between SCORAD means and neuroticism, extroversion, 
openness or agreeableness scores. Patients scoring low in Extraversion presented a higher 
SCORAD mean when compared to those scoring normal or high (p=0.065) (table 3). 
 
Multiple linear regression model for QoL 
Considering QoL, SCORAD was the main determinant for QoL (p = 0.002) with an adjusted 
R2 of 0.185. Disease duration was also an important determiner of QoL (p = 0.098) and, along 
with SCORAD, an adjusted R2 of 0.220 was achieved. Anxiety, depression and personality traits 
presented no significant association with QoL.  
  
DISCUSSION 
 
We found that patients scoring higher in HADS-D apparently had a higher scores in 
SCORAD. No study, so far, has succeeded in presenting a relation between a more severe disease 
and higher levels of depression. While anxiety levels were clearly higher in AD patients when 
comparing to healthy controls in previous studies 22, no study had yet proved any relation with 
AD severity. Similarly, our results suggested that anxiety levels may not differ concerning disease 
severity. 
Our study presented a prevalence of anxiety and depression of 34% and 14% respectively. 
When comparing with  previously published results of the Portuguese population’s scores, AD 
patients presented higher mean scores in both anxiety and depression than healthy individuals 18. 
In fact, when evaluating patients scoring moderate or severe in HADS-A and HADS-D, AD 
patients presented similar scores to epileptic patients (13% vs 14% for anxiety and 2% vs 7% for 
depression). When comparing our sample of Portuguese AD patients with AD patients from 
Germany 23 and United Kingdom 24 our sample scored lower in both anxiety and depression. 
Nevertheless those differences may had occurred due to different selection criteria (free-will vs 
paid participation) as well as cultural differences (baseline anxiety and depression values may 
vary according to different cultures). 
When assessing possible variables that could be directly influencing the severity of AD, 
neither age, duration of the disease, patient’s gender, asthma or atopic status presented a 
significant correlation with SCORAD. This may be explained by the fact that personal experience 
of disease may be independent from individuals’ genetic features and most likely be influenced 
by psychological traits and life events. 
Regarding personality traits, little is known about their influence in disease severity. No 
study has yet been published comparing the 5-main domains of personality assessed by NEO-FFI 
and their relation with AD severity. Our results suggest that Conscientiousness may be an 
important determiner in disease severity, exerting a protector effect. This can be explained by the 
fact that the trait of conscientiousness describes an individual’s tendency to adhere to socially 
prescribed rules and norms for impulse control, to being task and goal-directed. This personal 
abilities may gain significant importance when dealing with a chronic and relapsing disease such 
as AD. As well, patients scoring low in extraversion tended to have higher SCORAD mean values: 
these patients also presented higher scores in Neuroticism, a negative emotional personality trait 
determining a risk profile for anxiety and depression. However, future studies with more 
participants are required in order to fully evaluate personality and establishing a personality 
profile that can be either protective or deleterious to AD severity. 
Since recruitment of participants was mainly held through advertisement in media, a 
selection bias may have occurred. In fact, in what personality traits are concerned, patients 
presenting higher levels of extroversion and openness to experience were more likely to be 
enrolled.  Also, our sample included mainly patients with long-term disease; hereby, even though 
disease duration presented no correlation with SCORAD, it may have influenced anxiety and 
depression levels due to AD. 
The psychological characterization of AD patients not only concerning psychological stress 
but also personality traits must be considered in AD management. Psychotherapeutic 
interventions may be considered an important therapeutic strategy to achieve disease control 
 
  
 Table 1 - Sample descriptive statistics (n = 44) 
Age (years) a 31 (13) 
Male b 17 (39) 
Female b 27 (61) 
Disease duration c 18 (2; 40) 
AD Severity b  
     Mild 11 (25) 
     Moderate 18 (41) 
     Severe 15 (34) 
Atopic status b  
     Atopic patients 32 (73) 
     Non-atopic patients 12 (27) 
Asthma status b  
     Asthmatic patients 27 (61) 
     Non-asthmatic patients 17 (39) 
DLQI b  
     No impact 2 (5) 
     Mild impact 11 (25) 
     Moderate impact 16 (36) 
     Severe impact 14 (32) 
     Extremely severe impact 1 (2) 
Anxiety b   
 Normal 29 (66) 
 Mild 9 (21) 
 Moderate 5 (11) 
 Severe 1 (2) 
Depression c  
 Normal 38 (86) 
 Mild 5 (11) 
  Moderate 1 (2) 
a Mean (SD) 
b N (%) 
c Median (min, max) 
DLQI – Dermatology Life Quality Index  
  
  
 
 
 
 
 
Table 2 - Distribution of scores in the 5-main personality domains of NEO-FFI (n = 44) 
 Very Low Low Normal High Very High 
Neuroticism 2 (5) 7 (16) 21 (48) 9 (21) 5 (11) 
Extroversion 1 (2) 1 (2) 18 (41) 14 (32) 10 (23) 
Openness 0 (0) 3 (7) 25 (57) 12 (27) 4 (9) 
Agreeableness 4 (9) 9 (21) 24 (55) 6 (14) 1 (2) 
Conscientiousness 1 (2) 11 (25) 20 (46) 11 (25) 1 (2) 
Values shown are N (%) 
 
 
  
  
 
Table 3 - One-way ANOVA comparing mean SCORAD values in each category of the 5-main 
domains of personality traits 
  SCORAD 
mean 
p-value 
Neuroticism 
Low 47 
0.960 Normal 45 
High 44 
Extraversion 
Low 83 
0.065 Normal 37 
High 47 
Openness 
Low 42 
0.722 Normal 48 
High 41 
Agreeableness 
Low 55 
0.186 Normal 38 
High 48 
Conscientiousness 
Low 41 
0.035 Normal 56 
High 31 
p-value was obtained through a one-way ANOVA test 
patients scoring very low and low or very high and high were grouped into low and high respectively 
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ANEXOS 
  1. Sinto-me tenso(a)
  2. Ainda gosto das coisas como costumava gostar
  9. Sinto uma espécie de medo, como se tivesse um aperto no estômago
  8. Sinto-me mais lento(a) ou vagaroso(a)
  7. Posso sentar-me à vontade e sentir-me relaxado(a)
  6. Sinto-me alegre
  5. Tenho preocupações que me passam pela cabeça
  4. Consigo rir-me e ver o lado divertido das coisas
  3. Tenho uma sensação de medo, como se algo terrível estivesse para acontecer
HADS
 (Traduzido e adaptado por Teresa McIntyre, Graça Pereira, Vera Soares, Luís Gouveia, Sofia Silva - 1999)
-
Código:
ano de ingresso cod. aluno
A maior parte do tempo Muitas vezes De vez em quando Nunca
Tanto quanto gostava Não tanto quanto gostava Só um pouco do que gostava Quase nada do que gostava
Sim, e muito forte Sim, mas não muito forte Um pouco, mas isso não me preocupa Não, de maneira nenhuma
A maior parte do tempo Agora não tanto como costumava conseguir
Definitivamente não tanto como costumava conseguir Não, de maneira nenhuma
A maior parte do tempo Muitas vezes De vez em quando, mas não muitas vezes Apenas ocasionalmente
Nunca Poucas vezes Ás vezes A maior parte do tempo
Nunca Poucas vezes Ás vezes A maior parte do tempo
Quase sempre Muitas vezes Ás vezes Nunca
Quase sempre Muitas vezes Ás vezes Nunca
12. Antecipo as coisas com satisfação
11. Sinto-me inquieto(a), como se tivesse que estar sempre a andar de um lado para o outro
10. Perdi o interesse pela minha aparência
Sim, definitivamente Não me cuido tanto como devia Talvez não me cuide tanto como antes Cuido-me tanto como costumava
Sim, muito Sim, bastante Não muito Não, de modo nenhum
Tanto como eu costumava fazer anteriormente Um pouco menos do que anteriormente
Muito menos que anteriormente Quase nunca
13. Tenho sentimentos súbitos de ataques de pânico
Com muita frequência Bastantes vezes Não muitas vezes Nunca
14. Consigo apreciar um bom livro, um programa de televisão ou de rádio
Frequentemente Às vezes Poucas vezes Muito raramente
INSTRUÇÕES 
As emoções desempenham um papel importante na maior parte das doenças. Este questionário visa ajudar-nos a saber 
como se sente. Leia cada frase e sublinhe a resposta que mais se aproxima da forma como se tem sentido nos últimos 
tempos. Não passe muito tempo com cada resposta. Leia todas as frases num grupo antes de fazer a sua escolha. 
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4. Tento ser delicado com todas as pessoas que encontro
1. Não sou uma pessoa preocupada
2. Gosto de ter muita gente à minha volta
3. Não gosto de perder tempo a sonhar acordado(a)
6. Sinto-me muitas vezes inferior às outras pessoas
7. Rio facilmente
8. Quando encontro uma maneira correcta de fazer qualquer coisa não
mudo mais
9. Frequentemente arranjo discussões com a minha família e colegas de
trabalho
10. Sou bastante capaz de organizar o meu tempo de maneira a fazer as
coisas dentro do prazo
11. Quando estou numa grande tensão sinto-me, às vezes, como se me11. Quando estou numa grande tensão sinto-me, às vezes, como se me
estivessem a fazer em pedaços
12. Não me considero uma pessoa alegre
13. Fico admirado(a) com os modelos que encontro na arte e na natureza
(A codificar pelo Investigador)
5. Mantenho as minhas coisas limpas e em ordem
14. Algumas pessoas pensam que sou invejoso(a) e egoísta
15. Não sou uma pessoa muito metódica (ordenada)
16. Raramente me sinto só ou abatido(a)
17. Gosto muito de falar com as outras pessoas
18. Acredito que deixar os alunos ouvir pessoas, com ideias discutíveis, só
os pode confundir e desorientar
19. Preferia colaborar com as outras pessoas do que competir com elas
20. Tento realizar, conscienciosamente, todas as minhas obrigações.
20. Tento realizar, conscienciosamente, todas as minhas obrigações
21. Muitas vezes sinto-me tenso(a) e enervado(a)
22. Gosto de estar onde está a acção
23. A poesia pouco ou nada me diz
24. Tendo a ser descrente ou a duvidar das boas intenções dos outros
25. Tenho objectivos claros e faço por atingi-los de uma forma ordenada
26. Às vezes sinto-me completamente inútil
27. Normalmente prefiro fazer as coisas sozinho(a)
28. Frequentemente experimento comidas novas e desconhecidas
29. Penso que a maior parte das pessoas abusa de nós, se as deixarmos
30. Perco muito tempo antes de me concentrar no trabalho
NEO-FFI
Lima & Simões (2000)
Leia cuidadosamente cada uma das afirmações que se seguem e assinale com uma cruz o que
melhor representa a sua opinião. Responda a todas as questões.
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34. A maioria das pessoas que conheço gostam de mim
31. Raramente me sinto amedrontado(a) ou ansioso(a)
32. Muitas vezes, sinto-me a rebentar de energia
33. Poucas vezes me dou conta da influência que diferentes ambientes
produzem nas pessoas
36. Muitas vezes aborrece-me a maneira como as pessoas me tratam
37. Sou uma pessoa alegre e bem disposta
38. Acredito que devemos ter em conta a autoridade religiosa quando se
trata de tomar decisões respeitantes à moral
39. Algumas pessoas consideram-me frio(a) e calculista
40. Quando assumo um compromisso podem sempre contar que eu o
cumpra
11. Quando estou numa grande tensão sinto-me, às vezes, como se me41. Muitas vezes quando as coisas não me correm bem perco a coragem e
tenho vontade de desistir
42. Não sou um(a) grande optimista
43. Às vezes ao ler poesia e ao olhar para uma obra de arte sinto um arrepio
ou uma onda de emoção
35. Trabalho muito para conseguir o que quero
44. Sou inflexível e duro(a) nas minhas atitudes
45. Às vezes não sou tão seguro(a) ou digno(a) de confiança
como deveria ser
46. Raramente estou triste ou deprimido(a)
47. A minha vida decorre a um ritmo rápido
48. Gosto pouco de me pronunciar sobre a natureza do universo e da
condição humana
49. Geralmente procuro ser atencioso(a) e delicado(a)
20. Tento realizar, conscienciosamente, todas as minhas obrigações.
50. Sou uma pessoa aplicada, conseguindo sempre realizar o meu trabalho
51. Sinto-me, muitas vezes, desamparado(a), desejando que alguém
resolva os meus problemas por mim
52. Sou uma pessoa muito activa
53. Tenho muita curiosidade intelectual
54. Quando não gosto das pessoas faço-lhe saber
55. Parece que nunca consigo ser organizado(a)
56. Já houve alturas em que fiquei tão envergonhado(a) que desejava
meter-me num buraco
57. Prefiro tratar da minha vida a ser chefe das outras pessoas
58. Muitas vezes dá-me prazer brincar com teorias e ideias abstractas
59. Se for necessário não hesito em manipular as pessoas para conseguir aquilo
que quero
60. Esforço-me por ser excelente em tudo o que faço
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